Risankizumab(75Mg/0.83Ml) shortage status
No active shortage currently reported by the regulators Mederti tracks.
Last updated 22 Feb 2026 · sourced from official medicines regulators
- Generic name (INN)
- Risankizumab(75Mg/0.83Ml)
- Brand names
- Skyrizi Solution For Injection In Pre-Filled Syringe
- Class
- Auto-created by Health Sciences Authority — Singapore Post-Registration Actions scraper
Recent shortage history
- Singapore: resolved 24 Jan 2025 (began 24 Jan 2025)
Frequently asked questions
Is Risankizumab(75Mg/0.83Ml) currently in shortage?
No active shortage of Risankizumab(75Mg/0.83Ml) is currently reported by any of the national medicines regulators Mederti tracks. Shortages can emerge quickly — this page updates daily from official sources.
Where does this Risankizumab(75Mg/0.83Ml) shortage data come from?
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ official regulators across 35+ countries and never publishes unsourced shortage claims.
Get alerted when Risankizumab(75Mg/0.83Ml) status changes
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.